DSGN
Design Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.35 EPS
Last earnings +0.0% on 2026-04-28
$13.44▲ +259.36%
over 1Y
L $3.37EODHDH $15.79
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W+8.0%
1M+17.9%
3M+25.5%
YTD+47.7%
1Y+259.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Strong Buy
Pre-revenue clinical-stage biotech with one binary Phase 1/2 readout, recent clinical-hold history and ongoing dilution — not investable for most retail.
Design Therapeutics is a pre-revenue, clinical-stage biotech whose entire equity story rides on its GeneTAC platform and, in the near term, a single asset — DT-216P2 in Friedreich ataxia. FY2025 revenue was $0, net income was -$69.8M (worsening from -$49.6M), and operating cash burn ran at -$54.4M while R&D expense jumped +33.3% YoY to $59.1M. Diluted shares outstanding grew 8.6% to 61.7M, signaling that equity issuance is already part of the funding mix. At $14.30 the implied market cap is ~$882M against $213M of book equity and a -$297M accumulated deficit — i.e. the price is paying entirely for an unproven pipeline.
Sources: SEC EDGAR (CIK 0001807120, latest 10-Q filed 2026-04-28) · analysis by claude-code · as of 6/25/2026, 2:49:14 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.